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1. Demographics of aging: the next 50 years
Aging has become a central issue in science and society
in view of demographic changes anticipated in the next
decades due to longevity and low birth rates [1–3]. The
steady growth of the world’s population from approximately
2.5 billion in 1950 to 6.4 billion today is expected to
increase even further to more than 9 billion by 2050 [4]
(Fig. 1). The reasons for living longer [5] involve a decline
in old-age mortality [6] due to advances in disease
management and drug discovery, which have been made
possible through continued economic stability. However,
despite these advances, today’s clinical practice faces an
increasing number of geriatric patients with multi-morbidity
that requires special care adjusted to the high age of the
patients.
2. Aging theories—all for one and one for all?
Age remains the main cause of death after age 28 in
industrialized nations [7]. The majority of aging theories
favors cumulative injury resulting in cellular senescence as a
causative mechanism [8]. This results in genomic instability
caused by DNA damage that varies between aging organ
systems [9] and can be accelerated by reducing DNA repair
capacity of the cell [10]. Since evidence also suggests that
even within the same organ, aging may differently affect
activity of proteins [11], aging is likely to exhibit distinct
and specific rather than generalized responses, many of
which are still not known. Concepts such as the bfree radical
theory of agingQ proposed by Denham Harman in the 1950s
[1,8] have suggested general mechanisms including oxida-
tive stress to be predominantly responsible for cellular
injury with aging. Evidence presented in recent years
suggests that increased oxidative stress may indeed accel-
erate aging, at least in studies using short-lived species such
as flies, nematodes, and laboratory animals [12].
Aging in humans, a blong-livedQ species compared with
those mentioned above, is far more complex than in other
species, and, thus, knowledge obtained from non-human
species should be applied with caution [13]. For example,
human aging is associated with distinct metabolic changes
such as impaired insulin sensitivity and altered steroid
hormone function and lipid metabolism that require
decades to develop. Aging also alters the body’s respon-
siveness to dietary sodium and drugs and increases the
activity of the sympathetic nervous system [8]. It is likely
that these alterations contribute to some extent to the
functional and structural changes found in aged human
organ systems [14]. Moreover, after the fifth decade of life,
a decrease in human skeletal muscle mass known as
sarcopenia occurs [14], affecting approximately 25% of
individuals aged 65 years and older and up to half of
individuals above age 80 [14].
3. Cardiovascular aging: a point of no return?
The major cause of death worldwide currently continues
to be cardiovascular disease, which affects aged men and
women equally [15,16]. Given the anticipated growth of the
aged population [5] (Fig. 1), the number of patients with
cardiovascular risk factors and disease is expected to
increase sharply, making early recognition, prevention,
and treatment of risk factors and cardiovascular disease a
pivotal issue [17]. Surprisingly, the aging cardiovascular
system exhibits distinct changes that show a high degree of
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similarity between humans and rodents such as reduction in
vascular and myocardial compliance as well as the develop-
ment of vascular changes that can be modified by treatment
[18].
Previously, aging has been viewed as bdeteriorative
changes with time during postmaturational life that under-
lie an increasing vulnerability to challenges, decreasing the
ability of the organism to surviveQ [19]. This bdeteriorative
viewQ of aging resulting in gradual and irreversible loss of
organ function has been recently challenged by interven-
tion-induced improvement of age-related changes in the
cardiovascular [20,21] and the central nervous system
[22,23]. Surprisingly, certain neurological functions such
as the ability to discriminate motion may actually improve
with aging even in the absence of therapy [24], which
indicates that there is need for more research on the
physiology of aging.
4. Aging-associated bdiseasesQ: prevention rather than
treatment
Much of the research on aging in recent years has been
directed towards deciphering mechanisms and identifying
targets that allow interference with the aging process and/or
extension of life span. This Spotlight Issue of Cardiovas-
cular Research features several viewpoints on important
aspects of molecular, genetic, metabolic, and pathological
changes related to cardiovascular aging written by experts in
these fields. These articles not only summarize the current
state of knowledge, but also illustrate the necessity to further
and thoroughly investigate the mechanisms underlying the
pathobiology of human aging.
Though solid scientific evidence is still lacking, the
pharmaceutical and cosmetic industries over the years have
devoted much activity to the economically rewarding field
of aging bpreventionQ.
Although there is a general desire for rejuvenation that is
largely fueled by psychological and social factors, efforts
should not be focused on finding banti-agingQ remedies.
Rather, aging should be accepted as a physiologic process
that does not require intervention but allows a high quality
of life if the right steps are taken in due time.
What can we do to enable humans to bage gracefullyQ
and to reduce the disease prevalence of many of the age-
associated morbidities or to even prevent these morbidities
that we are encountering in many of today’s aged patients?
These individuals frequently exhibit conditions favoring the
development of hypertension, dyslipidemia, and atheroscle-
rosis, including a high prevalence of obesity, lack of
exercise, and unfavorable dietary regimens [17]. Unfortu-
nately, these conditions are not limited to aged individuals
but are already present to a considerable degree in juveniles
[17,25]. It will thus require timely and powerful intervention
if we want to avoid future disease in adulthood and even
later in life.
Despite the availability of simple interventions such
as improving cardiovascular fitness, a powerful tool to
reduce cardiovascular mortality [26], improve plasticity
in the aging human brain [23], and reduce immunose-
nescence [27] and even oxidative stress [28], or simply
cutting down on food intake and maintaining a healthy
body weight to delay aging-related changes [29–31], the
potential of many of these measures is far from being
fully recognized and is much underused. The goal of
our efforts should not be to enable humans to live as
long as possible but rather to have a life for as long as
possible. Therefore, providing information to allow early
prevention of disease will be the first step to successful
aging.
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